Atezolizumab in Combination with Obinutuzumab and Lenalidomide Demonstrates Favorable Activity and Manageable Toxicity in Patients with Relapsed/Refractory Follicular Lymphoma (FL): An Interim Analysis of a Phase Ib/II Trial

Affiliation auteurs!!!! Error affiliation !!!!
TitreAtezolizumab in Combination with Obinutuzumab and Lenalidomide Demonstrates Favorable Activity and Manageable Toxicity in Patients with Relapsed/Refractory Follicular Lymphoma (FL): An Interim Analysis of a Phase Ib/II Trial
Type de publicationJournal Article
Year of Publication2018
AuteursSalles G, Ghosh N, Lossos IS, Palomba MLia, Mehta A, Casasnovas O, Stevens D, Abajo A, Nielsen T, Chitra S, Wenger M, Morschhauser F
JournalBLOOD
Volume132
Date PublishedNOV 29
Type of ArticleMeeting Abstract
ISSN0006-4971
DOI10.1182/blood-2018-99-114992